Compare Natera Inc. Common Stock (NTRA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vital Farms Inc — how do they compare? Natera Inc. Common Stock trades at $386.99 (market cap $57.03B), while Vital Farms Inc trades at $9 (market cap $382.95M). The key difference: Natera Inc. Common Stock is far larger — about 148.9× Vital Farms Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vital Farms Inc for 15 Days on average.
| NTRA | VITL | |
|---|---|---|
Market Cap | $57.03B | $382.95M |
Volume | 1,131,157 | 1,912,535 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $40.85 |
52-Week Low | $179.42 | $8.28 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $56.18B | $469.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Vital Farms (VITL) trades at $9.34, down 1.37% with bearish technical signals and mixed fundamentals. The company reported Q2 2026 revenue of $166 million (down 10.1% YoY) but beat expectations, while net income margins collapsed to near-zero levels. Recent news includes potential strategic options exploration and institutional buying activity despite challenging industry conditions.
The stock faces headwinds from egg pricing pressure and oversupply issues, though analyst consensus remains positive with a $13.11 price target. Key risks include margin compression and industry volatility, while potential upside exists from strategic alternatives and pasture-raised egg demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
